Literature DB >> 2306752

Interleukin-2-dependent long-term cultures of low-density lymphocytes allow the proliferation of lymphokine-activated killer cells with natural killer, Ti gamma/delta or TNK phenotype.

U Testa1, A Care, E Montesoro, C Fossati, G Giannella, R Masciulli, M Fagioli, D Bulgarini, D Habetswallner, G Isacchi.   

Abstract

We have developed a culture system for "long-term" growth of human lymphokine-activated killer (LAK) cells exhibiting an elevated, wide-spectrum antitumor cytotoxicity. The system allows the exponential growth of monocyte-depleted low-density lymphocytes in the presence of human serum and recombinant human interleukin-2 (10(3) U/ml), alone or in combination with interleukin-1 alpha or beta (both at 10 U/ml). Eighteen cultures were established from 18 normal adult donors. The membrane phenotypes of the final LAK cell population, assessed by a panel of monoclonal antibodies (mAb), consist of three main types: (a) NKH-1+, Ti alpha/beta-, Ti gamma/delta-, and CD3- lymphocytes; (b) NKH-1+, Ti alpha/beta-, Ti gamma/delta+, and CD3+ lymphocytes and (c) NKH-1+, Ti alpha/beta+, Ti gamma/delta- and CD3+ lymphocytes. Northern blot analysis showed that all these cell populations express relatively high levels of perforin RNA, particularly cells exhibiting the first phenotype. This culture system may provide a tool for cellular and molecular studies on the mechanisms of antitumor cytotoxicity, as well as the basis for new adoptive immunotherapy protocols in advanced center.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2306752     DOI: 10.1007/bf01742490

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  45 in total

Review 1.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

2.  Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells.

Authors:  W L Crump; L B Owen-Schaub; E A Grimm
Journal:  Cancer Res       Date:  1989-01-01       Impact factor: 12.701

3.  Monocyte-dependent induction of proliferation of human peripheral T cells by recombinant interleukin 2.

Authors:  E E Roosnek; M C Brouwer; J B Kipp; L A Aarden
Journal:  Eur J Immunol       Date:  1986-01       Impact factor: 5.532

4.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

5.  IL 2 alone is mitogenic only for Tac-positive lymphocytes in human peripheral blood.

Authors:  D S Taylor; J A Kern; P C Nowell
Journal:  J Immunol       Date:  1986-03-01       Impact factor: 5.422

6.  Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma.

Authors:  P M Anderson; F H Bach; A C Ochoa
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

Authors:  R I Fisher; C A Coltman; J H Doroshow; A A Rayner; M J Hawkins; J W Mier; P Wiernik; J D McMannis; G R Weiss; K A Margolin
Journal:  Ann Intern Med       Date:  1988-04       Impact factor: 25.391

8.  Functional studies on the precursors of human lymphokine-activated killer cells.

Authors:  J D Gray; H Y Shau; S H Golub
Journal:  Cell Immunol       Date:  1985-12       Impact factor: 4.868

9.  Modulation of human natural killer cell function by L-leucine methyl ester: monocyte-dependent depletion from human peripheral blood mononuclear cells.

Authors:  D L Thiele; P E Lipsky
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

10.  Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen).

Authors:  L L Lanier; T J Kipps; J H Phillips
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

View more
  5 in total

1.  Long-term culture of human LAK cells.

Authors:  U Testa; E Montesoro; D Bulgarini; G Isacchi; G Mastroberardino; F Calabresi; C Peschle
Journal:  Cytotechnology       Date:  1991-02       Impact factor: 2.058

2.  High release of tumor necrosis factor alpha, interferon gamma and interleukin-6 by adherent lymphokine-activated killer cells phenotypically derived from T cells.

Authors:  J Koberda; L Bergmann; P S Mitrou; D Hoelzer
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

3.  Induction of lymphokine-activated killer cells with low-dose interleukin 2 and interferon-gamma in oral cancer patients.

Authors:  K Yoneda; T Yamamoto; E Ueta; T Osaki
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

4.  Development of four donor-specific phenotypes in human long-term lymphokine-activated killer cell cultures.

Authors:  I Vollenweider; R Moser; P Groscurth
Journal:  Cancer Immunol Immunother       Date:  1994-11       Impact factor: 6.968

5.  Expression of perforin and serine esterases by human gamma/delta T cells.

Authors:  H Koizumi; C C Liu; L M Zheng; S V Joag; N K Bayne; J Holoshitz; J D Young
Journal:  J Exp Med       Date:  1991-02-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.